CY1121689T1 - Σκευασματα (s)-3-(4-((4-(μορφολινομεθυλ)βενζυλοξυ)-1-οξοϊσοϊνδολιν -2-υλ)πιπεριδινο-2,6-διονης - Google Patents
Σκευασματα (s)-3-(4-((4-(μορφολινομεθυλ)βενζυλοξυ)-1-οξοϊσοϊνδολιν -2-υλ)πιπεριδινο-2,6-διονηςInfo
- Publication number
- CY1121689T1 CY1121689T1 CY20191100467T CY191100467T CY1121689T1 CY 1121689 T1 CY1121689 T1 CY 1121689T1 CY 20191100467 T CY20191100467 T CY 20191100467T CY 191100467 T CY191100467 T CY 191100467T CY 1121689 T1 CY1121689 T1 CY 1121689T1
- Authority
- CY
- Cyprus
- Prior art keywords
- morpholinomethyl
- oxoisoindoline
- piperidino
- benzyloxy
- dione
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- IXZOHGPZAQLIBH-NRFANRHFSA-N (3s)-3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1h-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C1N([C@@H]2C(NC(=O)CC2)=O)CC2=C1C=CC=C2OCC(C=C1)=CC=C1CN1CCOCC1 IXZOHGPZAQLIBH-NRFANRHFSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
Abstract
Παρέχονται εδώ φαρμακευτικές συνθέσεις και μορφές μίας μόνον μοναδιαίας δοσολογίας της (S)-3-(4-((4-(μορφολινομεθυλ)βενζυλ)οξυ)-1-οξοϊσοϊνδολιν-2-υλ)πιπεριδινο-2,6-διόνης ή ενός φαρμακευτικά αποδεκτού στερεοϊσομερούς, προφαρμάκου, άλατος, επιδιαλυτώματος, υδρίτη ή κλαθράτης. Επίσης παρέχονται μέθοδοι θεραπευτικής αγωγής, διαχείρισης ή πρόληψης διαφόρων διαταραχών όπως καρκίνος, μία φλεγμονώδης νόσος και/ή μία ανοσο-σχετική διαταραχή.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361888419P | 2013-10-08 | 2013-10-08 | |
PCT/US2014/059424 WO2015054199A1 (en) | 2013-10-08 | 2014-10-07 | Formulations of (s)-3-(4-((4-(morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121689T1 true CY1121689T1 (el) | 2020-07-31 |
Family
ID=51743584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191100467T CY1121689T1 (el) | 2013-10-08 | 2019-05-03 | Σκευασματα (s)-3-(4-((4-(μορφολινομεθυλ)βενζυλοξυ)-1-οξοϊσοϊνδολιν -2-υλ)πιπεριδινο-2,6-διονης |
Country Status (34)
Country | Link |
---|---|
US (2) | US10080801B2 (el) |
EP (1) | EP3054927B1 (el) |
JP (1) | JP6562907B2 (el) |
KR (1) | KR102272274B1 (el) |
CN (1) | CN105899196B (el) |
AR (1) | AR100663A1 (el) |
AU (1) | AU2014332171C1 (el) |
BR (1) | BR112016007729B1 (el) |
CA (1) | CA2921436C (el) |
CL (1) | CL2016000816A1 (el) |
CR (1) | CR20160131A (el) |
CY (1) | CY1121689T1 (el) |
DK (1) | DK3054927T3 (el) |
EA (1) | EA032421B1 (el) |
ES (1) | ES2723891T3 (el) |
HR (1) | HRP20190733T1 (el) |
HU (1) | HUE044186T2 (el) |
IL (1) | IL244494B (el) |
LT (1) | LT3054927T (el) |
MX (1) | MX2016004342A (el) |
NI (1) | NI201600048A (el) |
NZ (1) | NZ716856A (el) |
PE (1) | PE20160550A1 (el) |
PH (1) | PH12016500301A1 (el) |
PL (1) | PL3054927T3 (el) |
PT (1) | PT3054927T (el) |
RS (1) | RS58688B1 (el) |
SA (1) | SA516370860B1 (el) |
SG (1) | SG11201600996UA (el) |
SI (1) | SI3054927T1 (el) |
TR (1) | TR201905874T4 (el) |
TW (1) | TW201605493A (el) |
UA (1) | UA117141C2 (el) |
WO (1) | WO2015054199A1 (el) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2536706B1 (en) | 2010-02-11 | 2017-06-14 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
KR102266509B1 (ko) | 2012-08-09 | 2021-06-16 | 셀진 코포레이션 | 면역-관련 및 염증성 질환의 치료 |
US9695145B2 (en) | 2013-01-22 | 2017-07-04 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
EP3145513B1 (en) | 2014-05-19 | 2023-11-15 | Celgene Corporation | 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
BR112021006318A2 (pt) * | 2018-10-01 | 2021-07-06 | Celgene Corp | terapia de combinação para o tratamento de câncer |
CN113597301A (zh) * | 2019-01-09 | 2021-11-02 | 细胞基因公司 | 包含(s)-4-(4-(4-(((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-4-基)氧基)甲基)苄基)哌嗪-1-基)-3-氟苄腈的药物组合物以及使用它的方法 |
US20220401483A1 (en) | 2019-11-07 | 2022-12-22 | Juno Therapeutics, Inc. | Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]-piperidine-2,6-dione |
JP2023531512A (ja) * | 2020-06-25 | 2023-07-24 | セルジーン コーポレーション | 併用療法を用いて癌を治療するための方法 |
US20220168403A1 (en) * | 2020-07-17 | 2022-06-02 | Geron Corporation | Subcutaneous telomerase inhibitor compositions and methods for using same |
WO2024064646A1 (en) | 2022-09-20 | 2024-03-28 | Celgene Corporation | Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
US5770589A (en) | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
CN1511420A (zh) | 2001-11-09 | 2004-07-07 | 松下电器产业株式会社 | 运动图像编码方法和装置 |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
ZA200607799B (en) | 2004-03-22 | 2008-06-25 | Celgene Corp | Methods of using and compositions comprising immuno-modulatory compounds for the treatment and management of skin diseases or disorders |
WO2005105088A2 (en) | 2004-04-23 | 2005-11-10 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
BRPI0517481A (pt) | 2004-11-12 | 2008-10-14 | Celgene Corp | método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica |
WO2006058008A1 (en) | 2004-11-23 | 2006-06-01 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
AU2006265019B2 (en) | 2005-06-30 | 2011-10-13 | Celgene Corporation | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds |
WO2007027527A2 (en) | 2005-08-31 | 2007-03-08 | Celgene Corporation | Isoindole-imide compounds and compositions comprising and methods of using the same |
CA2660806C (en) | 2006-08-30 | 2015-06-16 | Celgene Corporation | 5-substituted isoindoline compounds |
US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
EP2076260B1 (en) | 2006-09-15 | 2011-03-23 | Celgene Corporation | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
DK2420498T3 (en) | 2006-09-26 | 2017-08-14 | Celgene Corp | 5-substituted quinazolinone derivatives as anticancer agents |
JP2010522170A (ja) | 2007-03-20 | 2010-07-01 | セルジーン コーポレイション | 4’−o−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
PT3351240T (pt) | 2009-05-19 | 2019-06-21 | Celgene Corp | Formulações de 4-amino-2-(2,6-dioxopiperidin-3-il) isoindolino-1,3-diona |
EP2536706B1 (en) * | 2010-02-11 | 2017-06-14 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
-
2014
- 2014-07-10 UA UAA201605023A patent/UA117141C2/uk unknown
- 2014-10-07 WO PCT/US2014/059424 patent/WO2015054199A1/en active Application Filing
- 2014-10-07 ES ES14786429T patent/ES2723891T3/es active Active
- 2014-10-07 MX MX2016004342A patent/MX2016004342A/es unknown
- 2014-10-07 AU AU2014332171A patent/AU2014332171C1/en active Active
- 2014-10-07 JP JP2016521344A patent/JP6562907B2/ja active Active
- 2014-10-07 TW TW103134936A patent/TW201605493A/zh unknown
- 2014-10-07 RS RS20190490A patent/RS58688B1/sr unknown
- 2014-10-07 LT LTEP14786429.2T patent/LT3054927T/lt unknown
- 2014-10-07 HU HUE14786429 patent/HUE044186T2/hu unknown
- 2014-10-07 DK DK14786429.2T patent/DK3054927T3/da active
- 2014-10-07 KR KR1020167009333A patent/KR102272274B1/ko active IP Right Grant
- 2014-10-07 PE PE2016000431A patent/PE20160550A1/es unknown
- 2014-10-07 SI SI201431178T patent/SI3054927T1/sl unknown
- 2014-10-07 CA CA2921436A patent/CA2921436C/en active Active
- 2014-10-07 EP EP14786429.2A patent/EP3054927B1/en active Active
- 2014-10-07 EA EA201690741A patent/EA032421B1/ru not_active IP Right Cessation
- 2014-10-07 BR BR112016007729-6A patent/BR112016007729B1/pt active IP Right Grant
- 2014-10-07 AR ARP140103744A patent/AR100663A1/es unknown
- 2014-10-07 SG SG11201600996UA patent/SG11201600996UA/en unknown
- 2014-10-07 PL PL14786429T patent/PL3054927T3/pl unknown
- 2014-10-07 NZ NZ716856A patent/NZ716856A/en unknown
- 2014-10-07 TR TR2019/05874T patent/TR201905874T4/tr unknown
- 2014-10-07 CN CN201480055238.2A patent/CN105899196B/zh active Active
- 2014-10-07 US US14/508,719 patent/US10080801B2/en not_active Ceased
- 2014-10-07 PT PT14786429T patent/PT3054927T/pt unknown
-
2016
- 2016-02-12 PH PH12016500301A patent/PH12016500301A1/en unknown
- 2016-03-08 IL IL244494A patent/IL244494B/en active IP Right Grant
- 2016-03-15 CR CR20160131A patent/CR20160131A/es unknown
- 2016-04-03 SA SA516370860A patent/SA516370860B1/ar unknown
- 2016-04-06 NI NI201600048A patent/NI201600048A/es unknown
- 2016-04-08 CL CL2016000816A patent/CL2016000816A1/es unknown
-
2019
- 2019-04-17 HR HRP20190733TT patent/HRP20190733T1/hr unknown
- 2019-05-03 CY CY20191100467T patent/CY1121689T1/el unknown
-
2020
- 2020-09-23 US US17/030,272 patent/USRE49647E1/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121689T1 (el) | Σκευασματα (s)-3-(4-((4-(μορφολινομεθυλ)βενζυλοξυ)-1-οξοϊσοϊνδολιν -2-υλ)πιπεριδινο-2,6-διονης | |
CY1122064T1 (el) | Σκευασματα 4-αμινο-2- (2,6-διοξοπιπεριδιν-3-υλο)ισοϊνδολινο-1,3-διονης | |
CY1124622T1 (el) | Μεθοδοι θεραπειας του καρκινου με τη χρηση 3-(4-((4-(μορφολινομεθυλ)βενζυλ)οξυ)-1-οξοϊσοϊνδολιν-2-υλ)πιπεριδινο- 2,6-διονης | |
CY1124669T1 (el) | ΑΝΤΙ-ΟΙΣΤΡΟΓΟΝΙΚΑ ΦΑΡΜΑΚΑ ΤΕΤΡΑΫΔΡΟ-1Η-ΠΥΡΙΔΟ[3,4-b]INΔOΛIOY | |
CY1120939T1 (el) | Συνδυασμος ρεγοραφενιμπης και ακετυλοσαλικυλικου οξεος για τη θεραπευτικη αντιμετωπιση του ορθοκολικου καρκινου | |
CY1120903T1 (el) | Ενωσεις αμινοπυριδυλοξυπυραζολιου | |
CY1121592T1 (el) | Μια στερεη μορφη της υδροχλωρικης (s)-3-(4-((4-μορφολινομεθυλ)βενζυλ)οξυ)-1-οξοϊσοϊνδολιν-2-υλ)πιπεριδινο-2,6-διονης | |
CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
CY1123595T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 | |
MX2020010484A (es) | Derivados de heterociclilos sustituidos como inhibidores de cdk. | |
CY1117430T1 (el) | Μεθοδοι θεραπειας καρκινου χρησιμοποιωντας 3-(5-αμινο-2-μεθυλ-4-οξο-4η-κιναζολιν-3-υλ)-πιπεριδινο-2,6-διονη | |
CY1119227T1 (el) | Παραγωγα πυριδινης ως ηπιοι αναστολεις της rock | |
CY1123174T1 (el) | Φαρμακοτεχνικες μορφες(+)-2-[1-(3-αιθοξυ-4 μεθοξυ-φαινυλ)-2 μεθανοσουλφονυλ-αιθυλ]-4-ακετυλαμινοϊσοϊνδολινο-1,3-διονης | |
CY1124243T1 (el) | Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1 | |
EA201991884A3 (ru) | Ингибиторы g12c kras | |
UY35684A (es) | Formulación de inhibidores de la tirosina quinasa de bazo (syk) | |
EA201892119A1 (ru) | Лекарственный препарат, полученный путем комбинирования агониста fxr и arb | |
TR201906476T4 (tr) | Farmasötik formülasyonlar. | |
CY1121909T1 (el) | Παραγωγο του 4-(3-πυραζολυλαμινο)-βενζιμιδαζολιου ως αναστολεας της jak1 για την αγωγη του καρκινου | |
MX2018002487A (es) | Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinalozin-3-il)-pipe ridin-2,6-diona. | |
TW201713630A (en) | Substituted quinazoline compounds and methods of use thereof | |
MX2015015290A (es) | Compuestos furanona como inhibidores de quinasa. | |
EA202190043A2 (ru) | Замещенные гетероциклические производные как ингибиторы циклин-зависимой киназы (cdk) | |
JOP20160150B1 (ar) | مركبات كينازولين مستبدلة وطرق استعمالها | |
CU20160018A7 (es) | Composiciones farmacéuticas de compuestos que inhiben la actividadde tirosina cinasa y sus métodos de preparación |